This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NTN4 / Netrin-4 · IHC design guide
Design Immunohistochemistry for NTN4
Plan chromogenic paraffin IHC for NTN4 with the catalog antibody at 2–5 μg/ml (datasheet A07052-1). Use testis Leydig cells as a positive tissue control and adipose tissue adipocytes as a negative cell control (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NTN4 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Membranous and cytoplasmic staining (HPA tissue IHC) | |
| Staining pattern | Membranous and cytoplasmic staining in several tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A07052-1) | |
| Positive control | Testis+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Secreted protein may stain away from its producer cells (HPA tissue IHC) | |
| Regulation | Tissue-dependent expression (HPA tissue IHC) | |
| Isoform / epitope | 3 isoforms; signal peptide 1–18 is cleaved, so check epitope coverage (UniProt) |
Section 1
Recommended NTN4 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet A07052-1) with three published NTN4 paraffin-section protocols (PMC6527380; PMC3783308; PMC8784893).
| Sample | Paraffin-embedded human endometrial cancer tissue; fixative not specified (datasheet A07052-1) |
| Fixation | Image fixative and duration unreported (datasheet A07052-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A07052-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A07052-1) |
| Primary antibody | Rabbit anti-NTN4, 2-5 μg/ml (datasheet A07052-1) |
| Primary incubation | Overnight at 4 °C (datasheet A07052-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A07052-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NTN4-positive staining in leydig cells of testis (HPA tissue IHC: High). HPA tissue profile: Membranous and cytoplasmic expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet A07052-1); the lung study used citrate pH 6.0 with another antibody (PMC8784893).
Section 2
What Is the Expected NTN4 Staining Pattern?
NTN4 is secreted and is a major basement membrane component, with no transmembrane segment (UniProt Q9HB63). In IHC, expect extracellular or basement membrane signal alongside the membranous and cytoplasmic patterns HPA reports in several tissues (HPA tissue IHC). Leydig cells stain strongly; selected glandular, endothelial and cerebellar cells stain at medium levels (HPA tissue IHC). HPA rates the tissue staining Approved but reports low consistency with RNA expression (HPA tissue IHC).
| Strong Leydig cell staining, with extracellular or basement membrane signal where structures are discernible. | This fits the high Leydig cell signal observed in testis (HPA tissue IHC) and NTN4’s secreted, basement membrane location (UniProt Q9HB63). Score cellular and extracellular patterns separately; a secreted protein need not remain confined to the producing cell (UniProt Q9HB63). |
| Membranous or cytoplasmic signal in glandular cells, cortical endothelial cells, or cerebellar granular layer cells. | These patterns can be compatible with the HPA tissue profile: several glandular populations, cerebral cortex endothelial cells and cerebellar granular layer cells show medium staining (HPA tissue IHC). Check the named cell population and its expected level before calling a section positive. |
| Dominant nuclear staining, without the expected cellular or extracellular pattern. | Nuclear localisation is unsupported by the secreted, extracellular and basement membrane record (UniProt Q9HB63) and by HPA’s membranous and cytoplasmic tissue profile (HPA tissue IHC). Treat a nuclear-only result as suspect and investigate staining artefact before assigning it to NTN4 (general IHC practice). |
| Strong signal in a cell population HPA lists as not detected, such as adipocytes or lymph node germinal center cells. | This disagrees with those cell-specific observations (HPA tissue IHC). Consider antibody cross-reactivity or endogenous chromogenic detection activity (general IHC practice); a negative call for one cell population does not establish that every structure in its tissue must be unstained. |
| Broad, poorly bounded stain across tissue or no signal in testis Leydig cells. | Diffuse signal is hard to assign to cells or basement membranes and may reflect background (general IHC practice). Absent Leydig cell signal conflicts with the high testis observation (HPA tissue IHC); inspect section quality and assay controls before interpreting another tissue as NTN4 negative. |
💡Expected NTN4 appearanceCall a positive IHC result when staining is assignable to appropriate cells, with compatible extracellular or basement membrane distribution (UniProt Q9HB63): Leydig cells should be High, while listed glandular, endothelial or granular layer cells may be Medium (HPA tissue IHC); isolated nuclear or indiscriminate diffuse stain is suspect (UniProt Q9HB63; general IHC practice).
| Secreted topology and tissue localisation | NTN4 lacks a transmembrane segment and is a major basement membrane component (UniProt Q9HB63). Assess extracellular deposits alongside the membranous and cytoplasmic staining seen by HPA; cell staining and deposited protein may occupy different places (HPA tissue IHC; UniProt Q9HB63). |
| Processing and epitope coverage | The precursor has a 1–18 signal peptide and a 19–628 NTN4 chain (UniProt Q9HB63). If an antibody’s epitope is known, check whether it lies in the mature chain; the supplied record gives no epitope for the IHC antibody, so its coverage cannot be inferred. |
| Molecular forms | UniProt lists 3 isoforms and 4 glycosylation sites (UniProt Q9HB63). These features justify checking documented antibody epitope and isoform coverage when staining differs across samples. The supplied sources do not show which forms the IHC antibody detects or establish an IHC effect of glycosylation. |
| Strength and limits of tissue evidence | HPA rates the tissue IHC result Approved and lists rabbit pAb HPA049832 as IHC Approved (HPA tissue IHC; HPA antibodies). HPA also reports low staining–RNA consistency and notes that secretion can separate RNA and protein locations (HPA tissue IHC). RNA abundance alone should therefore not determine a cell-level IHC call. |
| Situation | Likely cause | Next action |
|---|---|---|
| No Leydig cell signal in a testis section. | Leydig cells are a high-staining population in HPA tissue IHC; a blank result may reflect an assay or section problem (HPA tissue IHC; general IHC practice). | Check tissue integrity, primary antibody and chromogenic detection controls, then review the chosen retrieval and dilution settings as general IHC variables (general IHC practice). No NTN4-specific retrieval setting or fixation sensitivity is supplied. |
| Brown signal covers much of the section without clear cell or basement membrane boundaries. | Diffuse chromogen can arise from nonspecific binding or endogenous detection activity (general IHC practice); it cannot by itself confirm NTN4’s extracellular location (UniProt Q9HB63). | Review the no-primary control and detection blocking, then optimise antibody concentration against a testis positive control and a suitable cell-specific negative comparator (general IHC practice; HPA tissue IHC). |
| Nuclei dominate the stain. | A nuclear-only pattern conflicts with NTN4’s secreted, extracellular localisation (UniProt Q9HB63) and HPA’s membranous and cytoplasmic profile (HPA tissue IHC). | Check the no-primary control, counterstain appearance and antibody specificity before scoring the nuclear signal as NTN4 (general IHC practice). Compare with expected Leydig cell and other cell-level patterns (HPA tissue IHC). |
| Adipocytes or lymph node germinal center cells appear strongly positive. | HPA lists those specific populations as not detected (HPA tissue IHC). Unexpected staining warrants checks for cross-reactivity or endogenous detection activity (general IHC practice). | Confirm the identity of stained cells on the counterstained section and review detection controls (general IHC practice). Compare cell types within the section; do not turn an HPA cell-specific negative observation into a whole-tissue rule. |
| IHC staining and tissue RNA levels disagree. | HPA reports low consistency between antibody staining and RNA expression and notes that secretion can separate protein from its RNA source (HPA tissue IHC). | Interpret localisation at the stained cell and extracellular structure level, alongside IHC controls (general IHC practice; UniProt Q9HB63). Record the disagreement without using RNA level alone to invalidate a controlled stain (HPA tissue IHC). |
| Can IF/ICC confirm the IHC localisation? | HPA calls NTN4 secreted but provides no ICC-IF images or main intracellular location; HPA049832 has IHC Approved status with no ICC status supplied (HPA subcellular; HPA antibodies). | Treat IF/ICC as a separate validation question. An IHC-positive result does not establish an IF/ICC pattern or antibody performance (HPA antibodies; HPA subcellular); use the separate IF/ICC guide for that application. |
Experiment evidence
IHC & IF images showing NTN4 staining
A07052-1 · IHCIHC analysis of NTN4 using anti-NTN4 antibody (A07052-1). NTN4 was detected in a paraffin-embedded section of human endometrial cancer tissu
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000074527-NTN4/tissue/cerebral+cortex#imid_13812549
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000074527-NTN4/tissue/colon#imid_13455617
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000074527-NTN4/tissue/liver#imid_13455626
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000074527-NTN4/tissue/kidney#imid_13455635
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NTN4 IHC & IF
🧪Run testis first and look for staining in Leydig cells (HPA: High in Leydig cells); use adipose tissue adipocytes as the negative tissue (HPA: Not detected in adipocytes). On the testis slide, unstained non-Leydig cells can provide an internal background reference, but their NTN4-negative status is not established by the supplied HPA row (HPA: Leydig cells only).
Positive control tissue: Testis (Leydig cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for NTN4; derive a cell-line control from the positive tissue's cell type (Leydig cells) and confirm it by RNA or western blot first.
Technical controls: Include no-primary (secondary-only) and concentration-matched rabbit isotype controls (caption: rabbit anti-NTN4), plus NTN4-knockout material or immunizing-peptide competition if available. Quench endogenous peroxidase for the testis HRP/DAB assay (caption: HRP/DAB), and check autofluorescence with an unstained section if using IF.
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A07052-1 paraffin-section caption does not state the fixative (caption: fixative unreported). The caption uses heat retrieval in EDTA at pH 8.0 and 2 μg/ml primary overnight at 4°C, but does not establish that retrieval is required (caption: retrieval and incubation conditions). Paraffin IHC has a documented example; whether frozen sections or IF are easier is unreported, and testis extracellular deposits should be scored separately from Leydig-cell staining because NTN4 is secreted into basement membrane and extracellular matrix (caption: paraffin section; UniProt Q9HB63 localization; HPA: High in Leydig cells).
HPA tissue IHC evidence for NTN4
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Testis | Leydig cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Endothelial cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced NTN4 IHC Tips
Troubleshoot paraffin section chromogenic IHC for NTN4 by checking retrieval, tissue pattern, controls, and scoring against its secreted basement membrane biology (UniProt Q9HB63).
What retrieval should I try first when NTN4 staining is weak?
Start with heat mediated antigen retrieval in EDTA at pH 8.0 (datasheet A07052-1). The selected paraffin section example used that retrieval before an overnight primary incubation at 4°C (datasheet A07052-1). If staining remains weak, adjust heating duration in small steps on matched sections while keeping the EDTA buffer constant, and inspect morphology after each change (standard IHC practice). Run a no primary control alongside a known staining section so increased signal can be distinguished from increased background (standard IHC practice). Judge improvement in extracellular and basement membrane regions as well as cells, because NTN4 is secreted and associated with basement membranes (UniProt Q9HB63).
Could fixation be hiding NTN4 in my paraffin sections?
The selected paraffin section caption does not state its fixative, so target specific fixation sensitivity for this antibody is unknown (datasheet A07052-1). Record the actual fixative and fixation interval for every specimen, and compare sections processed under matched conditions before assigning weak signal to fixation (standard IHC practice). If specimens differ in processing, test the same EDTA pH 8.0 retrieval and primary concentration across them, changing one variable at a time (datasheet A07052-1; standard IHC practice). Inspect nuclear and tissue morphology alongside NTN4 staining to identify damaged or poorly preserved areas (standard IHC practice). Do not infer fixation tolerance from observed tissue expression or predicted protein features (HPA tissue IHC; UniProt Q9HB63).
Where should NTN4 signal appear, and how should cellular staining be judged?
Examine basement membrane and extracellular regions first: NTN4 is secreted, has no transmembrane segment, and is a major basement membrane component (UniProt Q9HB63). HPA also reports membranous and cytoplasmic tissue staining, so cellular signal alone is not automatically discordant (HPA tissue IHC). Compare staining with local tissue structure on the counterstained section and document extracellular and cellular compartments separately (standard IHC practice). For a positive tissue reference, HPA reports high staining in testis Leydig cells and medium staining in cerebral cortex endothelial cells (HPA tissue IHC). Treat diffuse signal that ignores tissue boundaries as suspect until no primary and detection controls are clean (standard IHC practice).
Can an epitope choice change which NTN4 deposits are detected?
NTN4 has 3 annotated isoforms, and the supplied caption does not identify this antibody’s epitope or isoform coverage (UniProt Q9HB63; datasheet A07052-1). The precursor has a signal peptide at residues 1–18, while the annotated NTN4 chain spans 19–628 (UniProt Q9HB63). It also has 4 annotated glycosylation sites, so document any available epitope information before comparing staining across reagents (UniProt Q9HB63; standard IHC practice). Do not assign a missing deposit to a specific splice variant or glycan without epitope mapping and independent evidence (standard IHC practice). Compare compartment level patterns under matched retrieval and detection conditions before interpreting antibody disagreement (standard IHC practice).
How should I check NTN4 localisation by multiplex IF?
Use a marker for the expected cell type in a separate fluorescence channel and assess whether NTN4 lies around that cell or within it, because NTN4 is secreted and basement membrane associated (UniProt Q9HB63; standard IF practice). For a vascular question, an endothelial cell marker is pertinent because HPA reports NTN4 staining in cerebral cortex endothelial cells (HPA tissue IHC). Choose fluorophores after imaging unstained tissue for autofluorescence, and place the weaker signal in a cleaner spectral channel (standard IF practice). Adjust permeabilisation to the epitope location: an extracellular epitope may be accessible without it, whereas an intracellular epitope requires access through the membrane (standard IF practice). Verify IF performance independently; the supplied product example documents chromogenic paraffin IHC (datasheet A07052-1).
How can I reduce widespread brown staining without losing NTN4 deposits?
First compare a no primary section with the stained section to separate detection background from antibody associated signal (standard IHC practice). Block endogenous peroxidase before HRP detection, then check whether brown color persists in the no primary control (standard chromogenic IHC practice). The selected example used 10% goat serum, 2 μg/ml primary antibody overnight at 4°C, an HRP linked secondary, and DAB (datasheet A07052-1). If background remains high, titrate primary concentration and shorten chromogen development on matched sections while checking that expected extracellular deposits remain visible (standard IHC practice; UniProt Q9HB63). Review folds, edges, and necrotic regions separately before calling widespread staining NTN4 positive (standard IHC practice).
How should I score NTN4 staining across comparable sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define compartments before scoring, because NTN4 can occupy extracellular matrix and basement membrane while HPA also reports membranous and cytoplasmic staining (UniProt Q9HB63; HPA tissue IHC). For cellular staining, record percent positive cells and intensity, or calculate an H-score using a fixed scoring rule (standard IHC practice). For extracellular deposits, measure positive area or signal density per mm² of eligible tissue rather than assigning deposits to nearby cells (standard IHC practice). Normalize to the same eligible tissue compartment or cell population and exclude folds, necrosis, and section edges consistently (standard IHC practice). Hold retrieval, imaging, counterstain, and DAB development conditions constant across the comparison (standard IHC practice).
What would make an apparent NTN4 positive result unconvincing?
A structured extracellular or basement membrane pattern fits NTN4’s secreted localisation, while a dominant nuclear pattern would need independent confirmation (UniProt Q9HB63). Check cell identity before interpreting cellular signal: HPA reports high staining in testis Leydig cells but no detected staining in adipose tissue adipocytes (HPA tissue IHC). Staining restricted to section edges, folds, or necrotic material calls for repeat assessment in intact tissue (standard IHC practice). Brown signal in a no primary control raises concern about endogenous enzyme activity or detection background rather than NTN4 (standard chromogenic IHC practice). Interpret discordance with RNA cautiously because HPA reports low staining to RNA consistency and notes that secretion can separate protein from its site of expression (HPA tissue IHC).
Boster reagents
Best NTN4 / Netrin-4 IHC Antibodies
One human-reactive anti-NTN4 antibody has a real IHC image from a paraffin-embedded human endometrial cancer section (A07052-1 image caption); no IF image is supplied (catalog image list).
Real IHC data
Anti-NTN4 Antibody ®
Cat # A07052-1
A07052-1 is listed for human IHC (catalog applications and reactivity). Its IHC image shows a paraffin-embedded human endometrial cancer section with chromogenic detection (A07052-1 image caption).
Which to pick: Choose A07052-1 for human paraffin-section IHC; its image caption documents EDTA retrieval at pH 8.0 and primary antibody at 2 μg/ml (A07052-1 image caption). The fixative is unreported (A07052-1 image caption). No SKU in this payload is listed for IF/ICC or for species beyond human (catalog applications and reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9HB63 (NET4_HUMAN, Netrin-4).
- Human Protein Atlas. NTN4 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. NTN4 subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. NTN4 antibody validation summary (1 antibodies).
- The Netrin-4/Laminin γ1/Neogenin-1 complex mediates migration in SK-N-SH neuroblastoma cells. Cell adhesion & migration 2019 — PMC6527380.
- Identification of gene expression signature in estrogen receptor positive breast carcinoma. Biomarkers in cancer 2010 — PMC3783308.
- Netrin Family Genes as Prognostic Markers and Therapeutic Targets for Clear Cell Renal Cell Carcinoma: Netrin-4 Acts through the Wnt/β-Catenin Signaling Pathway. Cancers 2023 — PMC10216638.
- Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function. ERJ open research 2022 — PMC8784893.
- PubMed PMID:11038171 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NTN4 (Netrin-4). Expected localisation Membranous and cytoplasmic staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A07052-1). Validated IHC antibody: A07052-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Testis (Leydig cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human endometrial cancer tissue; fixative not specified (datasheet A07052-1); 2. Fixation: Image fixative and duration unreported (datasheet A07052-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A07052-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A07052-1); 8. Primary antibody: Rabbit anti-NTN4, 2-5 μg/ml (datasheet A07052-1); 9. Primary incubation: Overnight at 4 °C (datasheet A07052-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Secreted protein may stain away from its producer cells (HPA tissue IHC); Isoform / epitope: 3 isoforms; signal peptide 1–18 is cleaved, so check epitope coverage (UniProt); Regulation: Tissue-dependent expression (HPA tissue IHC). Evidence: UniProt Q9HB63, HPA tissue IHC · Approved, HPA ICC-IF · Secreted, Datasheet A07052-1, PMC6527380, PMC3783308. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NTN4/immunohistochemistry-ihc-guide.